- Study is the first to show the impact of cannabis use on population rates of psychosis, highlighting the potential public health impact of changes to cannabis legislation
- Link with psychosis was strongest in London and Amsterdam, where high potency cannabis is commonly available
- In Amsterdam, an estimated 5 in 10 new cases of psychosis are linked with high potency use; in London, an estimated 3 in 10 new cases are linked with high potency use.
Daily cannabis use, especially of high potency cannabis, is strongly linked to the risk of developing psychosis, according to a case-control study from 11 sites across Europe, published in The Lancet Psychiatry journal. In cities where high potency cannabis is widely available, such as London and Amsterdam, a significant proportion of new cases of psychosis are associated with daily cannabis use and high potency cannabis.
Many countries have legalised or decriminalised cannabis use, leading to concerns that this might result in an increase in cannabis use and associated harms. Observational studies and biological evidence support a causal link between cannabis use and psychosis, but until now, it has been unclear whether, at a population level, patterns of cannabis use influence rates of psychosis.
Dr Marta Di Forti, lead author from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London, UK, says: "Our findings are consistent with previous studies showing that the use of cannabis with a high concentration of THC has more harmful effects on mental health than the use of weaker forms. They also indicate for the first time how cannabis use affects the incidence of psychotic disorder at a population level." 
"As the legal status of cannabis changes in many countries and states, and as we consider the medicinal properties of some types of cannabis, it is of vital public health importance that we also consider the potential adverse effects that are associated with daily cannabis use, especially high potency varieties." 
The new study looked at 11 sites across Europe (and one in Brazil) . First, the researchers estimated the prevalence of psychosis by identifying all individuals with first episode psychosis who presented to mental health services between 2010 and 2015. Secondly, they compared 901 patients with first episode of psychosis with 1,237 healthy matched controls to understand the risk factors associated with psychosis.
The researchers collected information about participants' history of cannabis use and other recreational drugs. Using published data on levels of delta-6-tetrahydrocannabinol (THC), they estimated cannabis potency for the types of cannabis used by participants, and classified types as either high potency (over 10% THC) or low potency (under 10% THC).
Daily cannabis use was more common among patients with first episode psychosis, compared to controls. 29.5% (266/901) of patients reported using cannabis daily, compared with 6.8% (84/1237) of controls. High potency cannabis use was also more common among patients with first episode psychosis, compared to controls. 37.1% (334/901) of patients reported using high potency cannabis, compared with 19.4% (240/1237) of controls.
Once adjusted for other factors, the authors found that across the 11 sites, people who used cannabis on a daily basis were three times more likely to have a diagnosis of first episode psychosis, compared with people who had never used cannabis. This increased to five times more likely for daily use of high potency cannabis.
The authors estimate that one in five new cases (20.4%) of psychosis across the 11 sites may be linked to daily cannabis use, and one in ten (12.2%) linked to use of high potency cannabis.
Use of high potency cannabis was a strong predictor of psychotic disorder in Amsterdam and London, where high potency cannabis is widely available. In the Netherlands, the THC content reaches up to 67% in Nederhasj, and 22% in Nederwiet; in London, skunk-like cannabis (average THC 14%) represents 94% of the street market, whereas in countries like Italy, France, and Spain, herbal types of cannabis with THC content of less than 10% were still commonly used.
For example, in Amsterdam, four in 10 (43.8%) new cases of psychosis were estimated to be linked to daily cannabis use, and 5 in 10 (50.3%) new cases linked to high potency use . Corresponding rates in London were 21.0% for daily use, and 30.3% for high potency use.
If high potency cannabis were no longer available, the incidence of psychosis in Amsterdam would be expected to drop from 37.9 to 18.8 per 100,000 people per year; and in London from 45.7 to 31.9 per 100,000 people per year.
The authors note that the data on cannabis use was not validated by biological measures such as urine, blood or hair samples. But they note that the cut-off of 10% THC for potency is conservative. The estimates on potency also do not include the proportion of cannabidiol (CBD), another important component of cannabis.
Writing in a linked Comment, Dr Suzanne H Gage, University of Liverpool (UK), asks whether we can now be sure that daily and high potency cannabis use causes psychosis. "Unfortunately, not all the evidence utilising different methods is consistent about causality... It is perfectly possible that the association between cannabis and psychosis is bidirectional. [This study] adds a new and novel study design to the evidence available, which consistently indicates that for some individuals there is an increased risk of psychosis resulting from daily use of high potency cannabis. Given the changing legal status of cannabis across the world, and the associated potential for an increase in use, the next priority is to identify which individuals are at risk from daily potent cannabis use, and to develop educational strategies and interventions to mitigate this."
Peer-reviewed / Case-control study / People
NOTES TO EDITORS
The study was funded by the Medical Research Council, the European Community's Seventh Framework Program grant, Sao Paolo Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, and the Wellcome Trust.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office firstname.lastname@example.org
 Quotes direct from authors and cannot be found in the text of the Article.
 Sites included in the study: London (UK), Cambridge (UK), Amsterdam (Netherlands), Gouda and Voorhout (Netherlands), Paris (Val-de-Marne, France), Puy de Dôme (France), Madrid (Spain), Barcelona (Spain), Bologna (Italy), Palermo (Italy), Ribeirão Preto (Brazil).
 Data derive from the Population Attributable Fraction (PAF) which measures the population effect of an exposure by providing an estimate of the proportion of cases that would be prevented if the exposure (ie, daily/high potency cannabis use) were removed. The PAF assumes causality between daily/high potency cannabis use and first episode psychosis.
IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30048-3/fulltext
The Lancet Psychiatry